[{"Assets_0_Q2_USD":841317000.0,"CommonStockSharesOutstanding_0_Q2_shares":90403238.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-18007000.0,"NetIncomeLoss_1_Q2_USD":-5913000.0,"NetIncomeLoss_2_Q2_USD":-47731000.0,"StockholdersEquity_0_Q2_USD":377436000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":96905000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":167991000.0,"Ticker":"NBIX","CIK":"914475","name":"NEUROCRINE BIOSCIENCES INC","OfficialName":"Neurocrine Biosciences Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"9338885763.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180731"}]